Expertise in
1
conditions

Dr. Timothy J. Eberlein

Surgical Oncology
4921 Parkview Pl, Div Surg Oncology, Ste 5f, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
45 Years of Experience
Expertise in
1
conditions
4921 Parkview Pl, Div Surg Oncology, Ste 5f, 
Saint Louis, MO 

Overview

Timothy Eberlein is a Surgical Oncologist in Saint Louis, Missouri. Dr. Eberlein has been practicing medicine for over 45 years is highly rated in 1 condition, according to our data. His top areas of expertise are Breast Cancer, Malabsorption, Paget Disease of the Breast, Reconstructive Urology Surgery, and Nephrectomy.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Surgical Oncology

Licenses

Surgery in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

4921 Parkview Pl, Div Surg Oncology, Ste 5f, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Enrollment Status: Recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Behavioral, Other
Study Drugs: Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen
Study Phase: Phase 2
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Enrollment Status: Terminated
Publish Date: August 17, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: LS301
Study Phase: Phase 1/Phase 2
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Biological, Procedure
Study Drug: Mammaglobin-A DNA Vaccine
Study Phase: Phase 1
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Enrollment Status: Terminated
Publish Date: May 28, 2024
Intervention Type: Device, Biological, Drug, Procedure
Study Drugs: Durvalumab, Neoantigen DNA vaccine
Study Phase: Phase 1
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: July 01, 2020
Intervention Type: Biological
Study Phase: Phase 1
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: June 25, 2020
Intervention Type: Device, Behavioral, Procedure, Other
Study Phase: Phase 2
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 10 Less Clinical Trials

26 Total Publications

The Changing Paradigm of Surgical Education.
The Changing Paradigm of Surgical Education.
Journal: Journal of the American College of Surgeons
Published: November 21, 2023
Similar Doctors
Julie A. Margenthaler
Expertise in
14
conditions
Dr. Julie A. Margenthaler
Surgical Oncology | General Surgery
Expertise in
14
conditions
Dr. Julie A. Margenthaler
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Julie Margenthaler is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Margenthaler is highly rated in 14 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Mastectomy, and Lymphadenectomy. Dr. Margenthaler is currently accepting new patients.

Expertise in
21
conditions
Dr. William E. Gillanders
Surgical Oncology | General Surgery
Expertise in
21
conditions
Dr. William E. Gillanders
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Gillanders is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Gillanders is highly rated in 21 conditions, according to our data. His top areas of expertise are Breast Cancer, Hyperparathyroidism, Thyroid Cancer, Parathyroidectomy, and Mastectomy. Dr. Gillanders is currently accepting new patients.

Expertise in
14
conditions
Dr. Rebecca L. Aft
Surgical Oncology | General Surgery
Expertise in
14
conditions
Dr. Rebecca L. Aft
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Aft is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Aft is highly rated in 14 conditions, according to our data. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Mastectomy, and Lymphadenectomy. Dr. Aft is currently accepting new patients.

Frequently Asked Questions about Dr. Timothy J. Eberlein

How do I make an appointment with Dr. Timothy J. Eberlein?

You can book an appointment with Dr. Timothy J. Eberlein by calling their office at 314-362-8020. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Timothy J. Eberlein a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy J. Eberlein is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Timothy J. Eberlein specialize in?

While Dr. Timothy J. Eberlein is a Surgical Oncology, they have specific expertise in Breast Cancer, Malabsorption, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Timothy J. Eberlein participate in research or clinical trials?

Yes. Dr. Timothy J. Eberlein has published 26 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Timothy J. Eberlein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Timothy J. Eberlein accept my insurance?

Dr. Timothy J. Eberlein accepts most major insurance plans, including Humana. We recommend calling the office directly at 314-362-8020 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eberlein's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile